Together with the results of cell viability assays and western blotting, these data demonstrated that miR-106a-RARB could increase the viability of thyroid cancer cells by activating MEKK2-ERK1/2 and MEKK2-ERK5 pathway. This evidence concerns the gene MAPK3 and thyroid cancer.